Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 8Oxaliplatin 7Surveys and Questionnaires 5Methods 5Early Intervention, Educational 5Cyclophosphamide 5Cisplatin 5Paclitaxel 4Magnetic Resonance Spectroscopy 4Leucovorin 4Gemcitabine 4Fluorouracil 4Carboplatin 4veliparib 3aldesleukin 3Trastuzumab 3Specimen Handling 3Nivolumab 3Diathermy 3Cytoreduction Surgical Procedures 3sargramostim 2entinostat 2cemiplimab 2cediranib 2X-Rays 2Therapeutics 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Metformin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Canagliflozin × Gynecologic × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡